Literature DB >> 15247537

Antibasal ganglia antibodies and their relevance to movement disorders.

Davide Martino1, Gavin Giovannoni.   

Abstract

PURPOSE OF REVIEW: Recently, autoaggressive immunological responses were included among the causative agents of basal ganglia dysfunction. Autoaggressive immune-mediated illnesses secondary to group A beta-haemolytic streptococcal infections present with motor and psychiatric symptoms, due to basal ganglia involvement. These disorders have been associated with serum antineuronal antibodies, relatively specific to human basal ganglia tissue. This review summarizes the most recent studies concerning antibasal ganglia antibodies, focusing on the associated phenotypes and the hypotheses concerning their pathogenicity. RECENT
FINDINGS: The spectrum of post-streptococcal neuropsychiatric disorders associated with antibasal ganglia antibodies seems broader than previously recognized. Other than chorea, tics and obsessive-compulsive disorder, which constituted the bulk of previously described disorders associated with antibasal ganglia antibodies, post-streptococcal neuropsychiatric disturbances include a wider range of motor and behavioural abnormalities, in keeping with the multifunctional role of the basal ganglia. An encephalitis lethargica-like illness following streptococcal infection was reported, and unusual adult-onset movement disorders associated with antibasal ganglia antibodies were documented. Moreover, investigators provided preliminary evidence for a pathogenic role of autoantibodies in Sydenham's chorea, the prototypic post-streptococcal neuropsychiatric disorder.
SUMMARY: Antibasal ganglia antibodies are relatively specific in identifying post-streptococcal neuropsychiatric disorders, which constitute a wider spectrum of movement disorders than previously recognized. Although their sensitivity in diagnosing Sydenham's chorea seems excellent, it is not yet possible to extrapolate this sensitivity to all the recently identified post-streptococcal neuropsychiatric disorders. The antigens targeted by these autoantibodies and their pathogenic importance are currently under investigation. Preliminary evidence suggests that antibasal ganglia antibodies may be pathogenic.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15247537     DOI: 10.1097/01.wco.0000137532.76491.19

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  6 in total

Review 1.  Inflammation in neurodegenerative diseases.

Authors:  Sandra Amor; Fabiola Puentes; David Baker; Paul van der Valk
Journal:  Immunology       Date:  2010-02       Impact factor: 7.397

2.  One Decade Later: What has Gene Expression Profiling Told us About Neuronal Cell Types, Brain Function and Disease?

Authors:  Elva Díaz
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

Review 3.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System?

Authors:  Adrian Wills; Russell Dale; Gavin Giovannoni
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

5.  Altered theta oscillations and aberrant cortical excitatory activity in the 5XFAD model of Alzheimer's disease.

Authors:  Magdalena Elisabeth Siwek; Ralf Müller; Christina Henseler; Astrid Trog; Andreas Lundt; Carola Wormuth; Karl Broich; Dan Ehninger; Marco Weiergräber; Anna Papazoglou
Journal:  Neural Plast       Date:  2015-04-02       Impact factor: 3.599

6.  Group A Beta-Hemolytic Streptococcus-Induced Tic-Like Movement Disorder in an Adult: A Case Report.

Authors:  Usman Ilyas; Zaryab Umar; Dana Lin
Journal:  Cureus       Date:  2022-08-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.